Xinmin Wang1,2, Ying Wang1,2, Jialiang Hu1,2, Hanmei Xu1,2. 1. The Engineering Research Centre of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu, China. 2. State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, Nanjing, China.
Abstract
BACKGROUND: CD47 is a widely expressed transmembrane protein located on the surface of somatic cells. It mediates a variety of cellular processes including apoptosis, proliferation, adhesion, and migration. An important role for CD47 is the transmission of a "Don't eat me" signal by interacting with SIRPα on the macrophage surface membrane, thereby preventing the phagocytosis of normal cells. However, cancer cells can take advantage of this autogenous signal to protect themselves from phagocytosis, thus enabling immune escape. Blocking the interaction between CD47 and SIRPα has proven to be effective in removing cancer cells. The treatment of various cancers with CD47 monoclonal antibodies has also been validated. METHODS: We designed and synthesized a peptide (RS17), which can specifically bind to CD47 and block CD47-SIRPα signaling. The affinity of RS17 for CD47-expressing tumor cells was determined, while the inhibition of CD47-SIRPα signaling was evaluated in vitro and in vivo. RESULTS: The results indicated that RS17 significantly promotes the phagocytosis of tumor cells by macrophages and had a similar therapeutic effect compared with a positive control (CD47 monoclonal antibodies). In addition, a cancer xenograft mouse model was established using CD47-expressing HepG2 cells to evaluate the effect of RS17 on tumor growth in vivo. Using ex vivo and in vivo mouse models, RS17 demonstrated a high inhibitory effect on tumor growth. CONCLUSIONS: Based on our results, RS17 may represent a novel therapeutic peptide for cancer therapy.
BACKGROUND:CD47 is a widely expressed transmembrane protein located on the surface of somatic cells. It mediates a variety of cellular processes including apoptosis, proliferation, adhesion, and migration. An important role for CD47 is the transmission of a "Don't eat me" signal by interacting with SIRPα on the macrophage surface membrane, thereby preventing the phagocytosis of normal cells. However, cancer cells can take advantage of this autogenous signal to protect themselves from phagocytosis, thus enabling immune escape. Blocking the interaction between CD47 and SIRPα has proven to be effective in removing cancer cells. The treatment of various cancers with CD47 monoclonal antibodies has also been validated. METHODS: We designed and synthesized a peptide (RS17), which can specifically bind to CD47 and block CD47-SIRPα signaling. The affinity of RS17 for CD47-expressing tumor cells was determined, while the inhibition of CD47-SIRPα signaling was evaluated in vitro and in vivo. RESULTS: The results indicated that RS17 significantly promotes the phagocytosis of tumor cells by macrophages and had a similar therapeutic effect compared with a positive control (CD47 monoclonal antibodies). In addition, a cancer xenograft mouse model was established using CD47-expressing HepG2 cells to evaluate the effect of RS17 on tumor growth in vivo. Using ex vivo and in vivo mouse models, RS17 demonstrated a high inhibitory effect on tumor growth. CONCLUSIONS: Based on our results, RS17 may represent a novel therapeutic peptide for cancer therapy.
Authors: Branimir I Sikic; Nehal Lakhani; Amita Patnaik; Sumit A Shah; Sreenivasa R Chandana; Drew Rasco; A Dimitrios Colevas; Timothy O'Rourke; Sujata Narayanan; Kyriakos Papadopoulos; George A Fisher; Victor Villalobos; Susan S Prohaska; Maureen Howard; Muralidhar Beeram; Mark P Chao; Balaji Agoram; James Y Chen; Jie Huang; Matthew Axt; Jie Liu; Jens-Peter Volkmer; Ravindra Majeti; Irving L Weissman; Chris H Takimoto; Dana Supan; Heather A Wakelee; Rhonda Aoki; Mark D Pegram; Sukhmani K Padda Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Keith Syson Chan; Inigo Espinosa; Mark Chao; David Wong; Laurie Ailles; Max Diehn; Harcharan Gill; Joseph Presti; Howard Y Chang; Matt van de Rijn; Linda Shortliffe; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2009-08-04 Impact factor: 11.205
Authors: Deborah Hatherley; Stephen C Graham; Jessie Turner; Karl Harlos; David I Stuart; A Neil Barclay Journal: Mol Cell Date: 2008-07-25 Impact factor: 17.970